Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period

Similar documents
Peri-operative management of the surgical patient with diabetes GL059

Information for Patients

Title Peri-operative Guidelines for the Management of Patients with Diabetes. Author s job title Diabetes Specialist Nurse Department.

Updated August /08/2020

PERIOPERATIVE DIABETES GUIDELINE

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures

Management of Adults with Diabetes Undergoing Surgery and Elective Procedures Guidelines. Diabetes Inpatient Steering Group June 2016

How they work and when to take them. Diabetes Medications

Management of adults with diabetes undergoing surgery and elective procedures: Improving standards Summary

Management of adults with diabetes undergoing surgery and elective procedures: improving standards

Peri-operative Glucose Control Is it Important?

Dept of Diabetes Main Desk

Guideline for the perioperative management of diabetes for Adult patients undergoing surgery

Peri-operative Glucose Control Is it Important?

DIABETES INDICATIONS FOR INSULIN

Diabetes, Type 2 Management

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

The principles of insulin adjustment guidance

Oxford Kidney Unit. Preparing for your operation: information for people with chronic kidney disease

Insulin Therapies: An Educational Toolkit

Glucose Control drug treatments

Inpatient Diabetes 20/01/2015. What should I do? Hyperglycaemia why does it matter? Why are the BSLs unstable? BSL parameters

St Helens & Knowsley Teaching Hospitals Adult Inpatient Diabetes Management Guidelines v24

JBDS Peri-operative Guidelines Impact on Elective Diabetes Care

Injectable Therapies in Diabetes

Pre admission & surgery Pre-admission Nurses Association SIG Catherine Prochilo Credentialled Diabetes Nurse Educator Sat 23 March 2013

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

How can we improve outcomes in Type 2 diabetes?

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

STEP 3: Add or Substitute with one of

TYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS

Leicestershire Diabetes Guidelines: Insulin Therapy

There have been important changes in diabetes care which may not be covered in undergraduate textbooks.

Pharmacological Glycaemic Control in Type 2 Diabetes

Injectable Therapies in Diabetes

Inpatient Diabetes Care

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Table 1. Antihyperglycemic agents for use in type 2 diabetes

3. Cardiovascular Disease?

Peri-Operative Guidelines for Management of Diabetes Patients

Arrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol

Managing Hyperglycaemia in Acute (Adult) Inpatients Requiring Enteral Feeding Guidelines

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Injectable Therapies in Diabetes

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins

Diabetes medication pharmacology

Initiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

Drug Therapy for Diabetes Mellitus. Adj A/Prof Daniel Chew Dept of Endocrinology 8 th July 2017

MANAGEMENT OF TYPE 2 DIABETES

sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd

Diabetes Mellitus case studies. Jana Vinklerová

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University

Oral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

End of Life Diabetes Care

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

Drugs used in Diabetes. Dr Andrew Smith

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Guideline for antihyperglycaemic therapy in adults with type 2 diabetes

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Mr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)

Medical therapy advances London/Manchester RCP February/June 2016

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:

667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY

dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Guidelines for managing diabetes in Ramadan

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Physiology of Normoglycemia

Navigating the New Options for the Management of Type 2 Diabetes

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

Mellitus undergoing Surgery

Endoscopy or colonoscopy guidelines

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Pathogenesis of disease diabetic ketoacidosis

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

PLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES

empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly

Inpatient Diabetes and Hyperglycaemia. Philip Dyer Heart of England NHS Foundation Trust Birmingham

DIABETES DEBATE - IS NEW BETTER?

Insulin Management. By Susan Henry Diabetes Specialist Nurse

Bristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium

WHO Guidelines for Management of Diabetes in Low Resource Settings

Insulin Therapy Management. Insulin Therapy

Diabetes mellitus. Treatment

Search strategies key terms

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

Guidelines for the care of Children with Diabetes Mellitus undergoing Surgery

Gastroscopy - Oesophago-gastro duodenoscopy (OGD)

Transcription:

Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period Dr Ketan Dhatariya MBBS MSc MD MS FRCP Consultant in Diabetes and Endocrinology Norfolk and Norwich University Hospitals

A Few Disclosures This is a subject that has occupied me for the last several years and I tend to get a bit evangelical about it I m one of the lead authors on these

A Bit of Background Peri-operative hyperglycaemia is associated with poorer outcomes however that is measured compared with people who do not have diabetes There are differences in outcomes between those people known to have diabetes and those who are hyperglycaemic

Do High Glucose Levels Cause Harm? 3,184 unselected non-cardiac surgical patients in Atlanta, GA 20.2% known to have diabetes 7.9% had hyperglycaemia prior to surgery All patients 2.8 5.5 8.3 11.1 13.9 16.6 (mmol/l) Patients with diabetes Patients without diabetes Frisch A et al Diabetes Care 2010;33(8):1783-1788

Do High Glucose Levels Cause Harm? 3,184 unselected non-cardiac surgical patients in Atlanta, GA 17.2% of people had hyperglycaemia on the day of surgery (not known to have diabetes) 9.9% had post operative hyperglycaemia 2.8 5.5 8.3 11.1 13.9 16.6 All patients Patients with diabetes Patients without diabetes (mmol/l) Frisch A et al Diabetes Care 2010;33(8):1783-1788

Do High Glucose Levels Cause Harm? Frisch A et al Diabetes Care 2010;33(8):1783-1788

More Observational Data Observational data from 55 US hospitals over 5 years looked at the outcomes of 18,278 patients 11,633 of whom who had a BG measured pre op, on day 1 post op or day 2 post op 55.4 ± 15.3 years 65.7% women Kwon S et al Ann Surgery 2013;257(1):8-14

Outcomes High glucose levels were associated with poor outcomes But having diabetes was protective (?increased vigilance) Kwon S et al Ann Surgery 2013;257(1):8-14

In Addition.. Other data has confirmed the harm of high preoperative glucose levels in non-cardiac, non vascular surgery 30 day mortality rates for 989 patients with diabetes for each mmol/l increase in blood glucose, OR for mortality rose by 1.19 (CI 1.1-1.3) Noordzij PG et al EJE 2007;156(1):137-142

HbA1c and Outcome Post CABG 764 patients with T1DM undergoing CABG between 1997-2012 in Sweden For every 1% (9mmol/mol) rise in pre-operative HbA1c above 7% (53mmol/mol), there was an 18% increase in mortality or MACE Nyström T et al. JACC 2015;66(5):535-543

Maybe Is Pre-Op HbA1c a Reliable Indicator of Outcomes? A thorough recent systematic review concluded: Elevated preoperative HbA1c was not definitively associated with any postoperative morbidity or mortality in patients with diabetes mellitus. The studies included in this review were relatively heterogeneous, predominantly retrospective, and often contained small patient numbers, suggesting that good quality evidence is necessary Rollins KE et al Clinical Nutrition http://dx.doi.org/10.1016/j.clnu.2015.03.007

The Patient Journey Primary care Surgical outpatients Pre-operative assessment clinic Hospital admission Theatre and recovery Post-operative care Discharge

Back to the Title Fasted and consented but blood glucose 18mmol/L Prevention The pre-operative manipulation of diabetes drugs prior to the procedure This is for people who are due to miss only 1 meal

Insulins Once daily (evening) (e.g. Lantus or Levemir Tresiba Insulatard Humulin I ) Insuman Basal ) Day prior to admission Reduce dose by 20% Patient for a.m. surgery Check blood glucose on admission Day of Surgery / whilst on a VRIII Patient for p.m. surgery Check blood glucose on admission If a VRIII is being used* Continue at 80% of the usual dose Once daily (morning) (Lantus or Levemir Tresiba Insulatard Humulin I ) Insuman Basal ) Reduce dose by 20% Reduce dose by 20% Check blood glucose on admission Reduce dose by 20% Check blood glucose on admission Continue at 80% of the usual dose Twice daily (e.g. Novomix 30, Humulin M3 Humalog Mix 25, Humalog Mix 50, Insuman Comb 25, Insuman Comb 50 twice daily Levemir or Lantus ) No dose change Halve the usual morning dose. Check blood glucose on admission Leave the evening meal dose unchanged Halve the usual morning dose. Check blood glucose on admission Leave the evening meal dose unchanged Stop until eating and drinking normally Twice daily - separate injections of short acting (e.g. animal neutral, NovoRapid Humulin S, Apidra ) and intermediate acting (e.g. animal isophane Insulatard, Humulin I Insuman ) No dose change Calculate the total dose of both morning insulins and give half as intermediate acting only in the morning. Check blood glucose on admission Leave the evening meal dose unchanged Calculate the total dose of both morning insulins and give half as intermediate acting only in the morning. Check blood glucose on admission Leave the evening meal dose unchanged Stop until eating and drinking normally 3, 4 or 5 injections daily (e.g. an injection of mixed insulin 3 times a day or 3 meal time injections of short acting insulin and once or twice daily background) No dose change Basal bolus regimens: omit the morning and lunchtime short acting insulins. Keep the basal unchanged.* Premixed am insulin: halve the morning dose and omit lunchtime dose. Check blood glucose on admission Take usual morning insulin dose(s). Omit lunchtime dose. Check blood glucose on admission Stop until eating and drinking normally

Tablets Day prior to admission Patient for a.m. surgery Day of Surgery / whilst on a VRIII Patient for p.m. surgery If a VRIII is being used* Acarbose Take as normal Omit morning dose if NBM Give morning dose if eating Stop once VRIII commenced, do not recommence until eating and drinking normally Meglitinide (repaglinide or nateglinide) Take as normal Omit morning dose if NBM Give morning dose if eating Stop once VRIII commenced, do not recommence until eating and drinking normally Metformin (egfr is greater than 60 ml/min/1.73m 2 and procedure not requiring use of contrast media**) Take as normal If taken once or twice a day take as normal If taken three times per day, omit lunchtime dose If taken once or twice a day take as normal If taken three times per day, omit lunchtime dose Stop once VRIII commenced, do not recommence until eating and drinking normally Sulphonylurea (e.g. glibenclamide, gliclazide, glipizide, glimeperide) Take as normal If taken once daily in the morning omit the dose that day If taken twice daily omit the morning dose that day If taken once daily in the morning omit the dose that day If taken twice daily omit both doses that day Stop once VRIII commenced, do not recommence until eating and drinking normally Pioglitazone Take as normal Take as normal Take as normal Stop once VRIII commenced, do not recommence until eating and drinking normally DPP IV inhibitor (e.g. sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin) Take as normal Take as normal Take as normal Stop once VRIII commenced, do not recommence until eating and drinking normally GLP-1 analogue (e.g. exenatide, liraglutide, lixisenatide, dulaglutide) Take as normal Take as normal Take as normal Take as normal SGLT-2 inhibitors (e.g. dapagliflozin, canagliflozin, empagliflozin) Take as normal Omit on day of surgery Omit on day of surgery Stop once VRIII commenced, do not recommence until eating and drinking normally

More Than 1 Missed Meal / Urgent Variable rate intravenous insulin infusion (VRIII) Or if the surgery is urgent and glycaemic control cannot be optimised prior to surgery aim for blood glucose values between 6.0 and 10.0 mmol/l (although 6.0 to 12.0 mmol/l is acceptable)

Back to the Title Fasted and consented but blood glucose 18mmol/L I ll assume this is pre-operative

That Depends on the Patient For people with type 1 Give subcutaneous rapid acting insulin. Assume that 1 unit will lower glucose by 3mmol/L. Recheck glucose 1 hour later If it is not falling and surgery can be delayed, do so If surgery cannot be delayed then commence a VRIII

That Depends on the Patient For people with type 2 Give subcutaneous rapid acting insulin at a dose of 0.1units/kg. Recheck glucose 1 hour later If it is not falling and surgery can be delayed, do so If surgery cannot be delayed then commence a VRIII

Back to the Title Fasted and consented but blood glucose 18mmol/L What about post operative?

That Depends on the Patient For people with type 1 Give subcutaneous rapid acting insulin. Assume that 1 unit will lower glucose by 3mmol/L. But, if the patient is awake, then ask them what they would normally do in this situation Recheck glucose 1 hour later, and repeat once more if the glucose is >12.0mmol/L If it is not falling then consider commencing a VRIII

That Depends on the Patient For people with type 2 Give subcutaneous rapid acting insulin at a dose of 0.1units/kg. Recheck glucose 2 hour later, and if it is still >12.0mmol/L consider doubling the insulin dose and/or the response to the initial dose If it is not falling then consider commencing a VRIII

A Glimmer of Hope?

Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period www.norfolkdiabetes.com ketan.dhatariya@nnuh.nhs.uk @ketandhatariya